Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ...
The Food and Drug Administration rejected Moderna's new flu shot. This raises questions about what it means for the future of ...
THE VACCINE MAKER MODERNA decided this past week to tell the world about bad news it had received from the federal government ...
StockStory.org on MSN
MRNA Q4 deep dive: New vaccines, cost controls, and pipeline milestones shape outlook
Biotechnology company Moderna (NASDAQ:MRNA) announced in Q4 CY2025, but sales fell by 29.8% year on year to $678 million. Its ...
Drug observers puzzled by vaccine maker, which made a killing on COVID-19, failing to read the room with new administration. Moderna puts heat on FDA vaccines chief who's already been rebuked once by ...
Applied Materials shares surged after the semiconductor-equipment maker beat analysts’ quarterly earnings estimates.
FDA Refuses To Review Moderna mRNA Flu Vaccine and the US Could Miss Out on Next Generation Fu Shots
In a rare and surprising move, the FDA has issued a “Refusal to File” letter for Moderna’s mRNA-1010 influenza vaccine.
After a string of high-profile regulatory rebukes, Biohaven’s CEO believes red tape is getting in the way of patient well-being, particularly for those with rare diseases. | After a string of ...
The issue came down to the study design: control group participants over 65 did not receive the high-dose flu shot; instead, ...
The company is expecting additional readouts this year from studies of cancer vaccine intismeran autogene, which is being tested in late-stage trials.
Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results